Physician profile
Daniel Robert Green
NPI 1790929230
$12,714.31
in general payments reported to CMS, 2019-2025
42 companies · $2,212 in 2025
The $2,212 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,503 · 2020: $704 · 2021: $1,555 · 2022: $1,930 · 2023: $1,522 · 2024: $1,288 · 2025: $2,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,414 · Travel and Lodging: $1,608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,413.67 |
| Travel and Lodging | $1,607.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $2,229.33 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $2,018.39 | 2019-2025 | Watchman Flx, Avvigo Guidance System, Watchman |
| Abiomed | $1,901.67 | 2019-2025 | Impella |
| Amgen INC. | $684.52 | 2019-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $672.04 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $649.40 | 2019-2024 | Xarelto |
| Medtronic, INC. | $597.36 | 2021-2025 | Onyx Frontier, Ffrangio, Symplicity G3 |
| Cardiovascular Systems INC. | $564.57 | 2019-2023 | Diamondback Coronary |
| Astrazeneca Pharmaceuticals LP | $543.22 | 2019-2024 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $490.20 | 2019-2025 | Lifevest |
| Pfizer INC. | $374.41 | 2019-2023 | |
| Atricure, INC. | $241.03 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.64 | 2019-2023 | Jardiance |
| Genzyme Corporation | $147.83 | 2025 | |
| Sanofi-Aventis U.S. LLC | $141.21 | 2019 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $131.80 | 2021-2023 | Verquvo |
| Shockwave Medical, INC | $125.52 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Acist Medical Systems, INC. | $124.14 | 2022-2023 | |
| Biosense Webster, INC. | $121.12 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $91.37 | 2019-2023 | Eliquis |
| Amarin Pharma, INC. | $80.07 | 2019-2021 | |
| Medtronic Vascular, INC. | $75.45 | 2020 | |
| Philips North America LLC | $73.64 | 2024-2025 | Ambulatory Monitoring & Diagnostics Undivided, (5091) Amb Mon & Diag Und |
| Abbott Laboratories | $73.37 | 2022-2024 | Coroflow, Diamondback Coronary |
| Terumo Medical Corporation | $44.91 | 2024-2025 | Glidewire, Optitorque |
| Daiichi Sankyo INC. | $43.35 | 2021-2022 | |
| Gilead Sciences, INC. | $39.04 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.85 | 2022-2023 | |
| Kestra Medical Technology Services, INC. | $33.00 | 2023 | Assure Wcd |
| United Therapeutics Corporation | $22.80 | 2019 | |
| Lundbeck LLC | $22.03 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $21.14 | 2023 | Opsumit |
| Cvrx, INC. | $19.93 | 2023 | Barostim Neo System |
| Penumbra, INC. | $19.76 | 2024 | Indigo System |
| Bridgebio Pharma, INC. | $19.44 | 2025 | Attruby |
| Esperion Therapeutics, INC. | $17.92 | 2021 | |
| Medtronic USA, INC. | $14.77 | 2019 | |
| Cardiva Medical, INC. | $13.72 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Kiniksa Pharmaceuticals International, Plc | $13.35 | 2024 | Arcalyst |
| Bardy Diagnostics, INC. | $10.00 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.